gsk1572932a
Biologicalexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started May 11, 2007 (NCT00455572)
Timeline
Indications
Studied for
Mechanism of action
- Melanoma-associated antigen 3Immunity, active
MAGEA3 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gsk1572932a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00480025 | Phase 3 | Oct 1, 2007 | GlaxoSmithKline |
| NCT00455572 | Phase 1 | May 11, 2007 | GlaxoSmithKline |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 2 | 2 | 2 | 2007 |
1 organizations
Page 1 / 1